A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01761019 |
Recruitment Status :
Completed
First Posted : January 4, 2013
Results First Posted : September 21, 2016
Last Update Posted : September 21, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Psoriasis | Drug: Taclonex Topical Suspension | Phase 4 |
Many patients with mild psoriasis are able to control disease symptoms with topical medications alone. There are a variety of topical options available, including corticosteroids, synthetic vitamin D3, vitamin A, coal tar, salicylic acid and a number of other products of varying efficacy. The combination topical suspension of calcipotriene 0.005% and betamethasone dipropionate 0.064% is a first-line treatment for moderate to severe psoriasis vulgaris and is FDA approved for use on the skin and scalp in adults 18 years and older. This treatment combines the pharmacological effects of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. It is well tolerated and has a low rate of adverse events according to pooled safety data from 2700 patients who have used a calcipotriene/betamethasone combination in clinical trials. Calcipotriene/betamethasone topical suspension has also been shown to have a positive impact on patient quality of life, as seen in clinical trials utilizing patient reported outcomes such as the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index.
Calcipotriene/betamethasone topical suspension is a therapy commonly used to treat patients with mild to moderate psoriasis. Currently, there have been no formal trials studying the efficacy of calcipotriene/betamethasone topical suspension used in conjunction with methotrexate or acitretin. In order to better understand the effectiveness of this treatment combination, we conducted a preliminary, open label, single arm prospective study to determine the benefit of adding betamethasone-calcipotriene topical suspension to ongoing systemic psoriasis therapy in subjects who do not have complete clearance of psoriasis on a single systemic agent alone.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 8 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy |
Study Start Date : | January 2013 |
Actual Primary Completion Date : | September 2014 |
Actual Study Completion Date : | September 2014 |

Arm | Intervention/treatment |
---|---|
Taclonex topical suspension
Taclonex topical suspension will be used daily to affected areas of skin with psoriasis for 12 weeks
|
Drug: Taclonex Topical Suspension
topical medication for psoriasis |
- Investigator Global Assessment [ Time Frame: 12 weeks ]This is score from 0-5 that measures, in the opinion of the study doctor, the severity of psoriasis on a subject, with 5 being most severe and 0 least severe. The change in this score between baseline and week 12 will be measured.
- Body Surface Area [ Time Frame: 12 weeks ]This is a measure of the percentage of the body involved with psoriasis. We will measure the change in percentage of body area involved with psoriasis from baseline to week 12.
- Safety [ Time Frame: 12 weeks ]Throughout this study, adverse events and serious adverse events will be collected
- Patient Satisfaction [ Time Frame: 12 weeks ]• Subject satisfaction: We also ask subjects for their level of satisfaction with their current treatment at week 12. They will be given the following options: "very satisfied", "satisfied", "somewhat disappointed" or "very disappointed". For measurement "very satisfied"=4, "satisfied"=3, "somewhat disappointed"=2 and "very disappointed"=1. We will determine the mean satisfaction of all patients at week 12.
- Desire to Change to Another Systemic Therapy [ Time Frame: 12 weeks ]We will measure the difference in percent of subjects who wish to change to another systemic therapy at baseline vs at week 12.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects age 18 years and older with stable plaque psoriasis of duration of at least 6 months.
- Subject must be currently using a stable dose, with stable disease severity, of a single non-biologic systemic psoriasis medication (methotrexate or acitretin) for at least 2 months.
- Subject must be planning to continue current systemic agent, and standard of care monitoring for that medication
- All labs required for methotrexate or acitretin will be done according to standard of care.
- If a woman, before entry she must be: Postmenopausal, or practicing a highly effective method of birth control
- Women of childbearing potential must have a negative urine pregnancy test prior to randomization
- Subject must be able and willing to provide written informed consent to participate.
Exclusion Criteria:
- Non-plaque psoriasis (pustular, erythrodermic, or guttate).
- Use of excluded therapies: phototherapy use currently or in the 4 weeks prior to baseline, use of more than 1 systemic therapy in the 2 months prior to baseline, use of topical steroid, tar preparation, or vitamin D analog in the 4 weeks prior to baseline.
- Subjects who are currently taking or have taken in the past 60 days, for any reason, any medication that, in the opinion of the investigator, suppressed the immune response. This may include but is not limited to systemic steroids, azathioprine, cyclosporine, FK506, mycophenolate mofetil, mycophenolic acid, etanercept, adalimumab, infliximab, ustekinumab, cimzia, or any other biologic agent targeted to any cell or cytokine in the immune system.
- Subjects with any use at any time in the past of Taclonex topical suspension or Taclonex ointment
- Subjects who are pregnant, nursing, or plan on becoming pregnant during the course of the study.
- Presence of any unstable medical or psychiatric condition that, in the opinion of the investigator, could impair subject compliance.
- Subject has any active infection within 30 days prior to baseline.
- Known or suspected disorders of calcium metabolism
- Known or suspected severe kidney or liver disease.
- Known or suspected hypersensitivity to component(s) of the investigational products.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01761019
United States, Pennsylvania | |
UPMC Department of Dermatology, Falk Clinic | |
Pittsburgh, Pennsylvania, United States, 15213 |
Principal Investigator: | Laura Ferris, MD, PhD | University of Pittsburgh |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Laura Ferris, MD, PhD, University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT01761019 |
Other Study ID Numbers: |
PRO12100308 |
First Posted: | January 4, 2013 Key Record Dates |
Results First Posted: | September 21, 2016 |
Last Update Posted: | September 21, 2016 |
Last Verified: | August 2016 |
psoriasis Taclonex Acitretin Methotrexate |
Psoriasis Skin Diseases, Papulosquamous Skin Diseases |